Galderma launches Restylane® Volyme™ in China – one of the world’s fastest growing aesthetics markets Press release
Galderma receives filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in four additional countries Press release
Galderma delivers a strong start to the year with record net sales of over 1 billion USD for the first quarter and 12.4% year-on-year growth Press release
Galderma prices IPO at CHF 53 per share and will start trading on the SIX Swiss Exchange tomorrow Press release
Galderma @ AAD 2024: new data demonstrate the long-term efficacy of nemolizumab in prurigo nodularis and its durability in atopic dermatitis Press release
Galderma announces record 2023 net sales of over 4 B USD and significant core EBITDA margin expansion Press release
